Abstract. The mechanisms of drug resistance in cancer are not fully elucidated. To study the drug resistance of gastric cancer, we analyzed gene expression and DNA methylation profiles of 5-fluorouracil (5-FU)-and cisplatin (CDDP)-resistant gastric cancer cells and biopsy specimens. Drug-resistant gastric cancer cells were established with culture for >10 months in a medium containing 5-FU or CDDP. Endoscopic biopsy specimens were obtained from gastric cancer patients who underwent chemotherapy with oral fluoropyrimidine S-1 and CDDP. Gene expression and DNA methylation analyses were performed using microarray, and validated using real-time PCR and pyrosequencing, respectively. Out of 17,933 genes, 541 genes commonly increased and 569 genes decreased in both 5-FU-and CDDP-resistant AGS cells. Genes with expression changed by drugs were related to GO term 'extracellular region' and 'p53 signaling pathway' in both 5-FU-and CDDP-treated cells. Expression of 15 genes including KLK13 increased and 12 genes including ETV7 decreased, in both drug-resistant cells and biopsy specimens of two patients after chemotherapy. Out of 10,365 genes evaluated with both expression microarray and methylation microarray, 74 genes were hypermethylated and downregulated, or hypomethylated and upregulated in either 5-FU-resistant or CDDP-resistant cells. Of these genes, expression of 21 genes including FSCN1, CPT1C and NOTCH3, increased from treatment with a demethylating agent. There are alterations of gene expression and DNA methylation in drug-resistant gastric cancer; they may be related to mechanisms of drug resistance and may be useful as biomarkers of gastric cancer drug sensitivity.
Introduction
Gastric cancer is one of the most common causes of cancer-related mortality, responsible for >700,000 deaths worldwide per year (1) . Although the main treatment strategy for gastric cancer is surgical or endoscopic resection, unresectable cases are treated with systemic chemotherapy. Platinum agents and fluoropyrimidine are the key therapeutic drugs for advanced gastric cancer (2) and drug resistance is an important problem accompanying treatment. A number of studies have previously reported on the mechanisms of gastric cancer chemoresistance (3) using cultured cells, animal models and clinical tissue samples. However, the mechanisms of drug resistance have not been fully elucidated.
It has been reported that both genetic and epigenetic changes play important roles in carcinogenesis and tumor progression (4) . In various types of cancer, epigenetic changes are known to be early events in the multi-steps of carcinogenesis (5) . Promoter hypermethylation is well-known to be important for the suppression of tumor suppressor gene expression (4) . Mechanisms of cancer drug resistance are considered to be multifactorial; they have epigenetic alterations (6) and involve multiple gene functions and signaling pathways. A better understanding of such mechanisms may provide therapeutic strategies for gastric cancer.
In the present study, drug-resistant gastric cancer cell lines were established, and biopsy specimens were obtained from patients after the acquisition of drug resistance. Genome-wide analysis of gene expression and DNA methylation with a microarray for drug-resistant cell lines and endoscopic biopsy specimens of gastric cancer was performed. Validation with quantitative methods was also performed. (5-aza-dC) treatment. AGS was purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA), and cultured in RPMI-1640 medium with 10% FBS at 37˚C with 5% CO 2 . For treatment with 5-aza-dC (decitabine), cells were seeded on day 0, and exposed to freshly prepared 10 µmol/l 5-aza-dC (Sigma-Aldrich, Tokyo, Japan) for 24 h on days 1 and 3. After ) were cultured using 96-well microplates for 24 h, and exposed to various concentrations of CDDP or 5-FU for 48 h to calculate the IC 50 of CDDP or 5-FU for each cell line.
Materials and methods

Cell culture and 5-aza-2'-deoxycytidine
Patients and biopsy specimens. Endoscopic biopsy specimens were obtained from two patients with unresectable advanced gastric cancer who underwent 3 and 4 courses of chemotherapy with oral fluoropyrimidine S-1 plus CDDP (8) before and after treatment. Samples after chemotherapy were obtained from lesions with viable cancer. The present study was approved by the Ethics Committee of Nagoya University Graduate School of Medicine, and written informed consent was provided by the patients.
Extraction of DNA and RNA from cell lines and gastric biopsy specimens. Cells or biopsy specimens were stored at -80˚C for DNA extraction, and we used RNAlater (Ambion, Austin, TX, USA) for RNA extraction. For extraction of DNA and RNA, DNA Mini kit (Qiagen, Venlo, The Netherlands) and RNA Mini kit (Qiagen) were used, respectively.
Gene expression analysis with microarray. Expression analysis was performed with SurePrint G3 Human GE 8x60K (Agilent, Loveland, CO, USA). Expression of mRNA of autosomal 17,933 genes was evaluated with 23,856 corresponding probes. A difference in signal intensity >2-fold was judged to be significant. DNA methylation microarray. Bisulfite-converted DNA was used for hybridization on Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA). The β-value [intensity of the methylated allele (M)/(intensity of the unmethylated allele (U) + intensity of the methylated allele (M) + 100)] was calculated for each CpG site (9) . Methylation levels of candidate promoter lesions in CpG islands of 11,692 genes were evaluated. Genes with a difference in their β-value >0.1 were extracted. Of these 11,692 genes, expression of 10,365 genes was also evaluated with expression microarray.
Gene ontology (GO) and pathway analysis. GO analysis was performed with TargetMine (http://targetmine.nibio. go.jp/targetmine/begin.do; National Institute of Biomedical Innovation, Osaka, Japan), and pathway analysis was performed with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. GO terms or pathways with P<0.05 using the HolmBonferroni method were judged to be significantly enriched.
Real-time PCR. Real-time PCR was performed to validate expression of mRNA with TaqMan Gene Expression Assays and TaqMan Gene Expression Master Mix (both from Applied Biosystems, Foster City, CA, USA).
Bisulfite pyrosequencing. Bisulfite treatment was performed with the EpiTect kit (Qiagen) according to the manufacturer's protocol. PyroMark PCR (Qiagen) was used to perform PCR, and bisulfite pyrosequencing was performed as previously reported (10) (11) (12) . In brief, the biotinylated PCR product was captured on streptavidin-coated beads (Amersham Biosciences, Uppsala, Sweden) and run on the PSQHS Pyrosequencing System (Biotage, Uppsala, Sweden) to obtain the degree of methylation. 
Results
Resistance
Genes with altered expression in drug-resistant cells and biopsy specimens.
To characterize gene expression profiles of drug-resistant gastric cancer cells, expression microarray analysis was performed. A comparison of parent AGS, 5FUr and CDDPr change of expression is shown in Fig. 1 . The expression of 541 genes increased and the expression of 569 genes decreased in both 5FUr and CDDPr compared with parent AGS. In contrast, the expression of only 25 genes increased in 5FUr and decreased in CDDPr, and the expression of only seven genes decreased in 5FUr and increased in CDDPr. To examine the characterization of genes with expression altered by drug treatment, we performed GO analysis and pathway analysis (Table I) . Although most enriched GO terms differed between those changed in 5FUr and those changed in CDDPr, 'extracellular region' in GO terms of cellular component was commonly enriched in both 5FUr and CDDPr. With pathway analysis, the 'p53 signaling pathway' was enriched in both 5FUr and CDDPr.
To compare gene expression of gastric cancer before and after chemotherapy, expression microarray analysis with endoscopic biopsy specimens was performed. Genes with altered expression both in drug-resistant cells and in biopsy specimens after chemotherapy were extracted. The expression of 15 genes increased 5FUr, CDDPr and two pairs of biopsy specimens, and the expression of 12 genes decreased (Fig. 2, Table II) .
To validate the gene expression change extracted with microarray, real-time PCR for KLK13 and ETV7 was performed. Consistent with microarray analysis, KLK13 increased in both drug-resistant AGS cells and endoscopic biopsy specimens after chemotherapy (Fig. 3A) . In contrast, ETV7 decreased in both drug-resistant cells and biopsy specimens after treatment (Fig. 3B) .
Integrated analysis of expression and methylation microarray.
To study whether DNA methylation contributes to gene expression change caused by chemotherapy agents, we analyzed the methylation profiles of 5FUr and CDDPr and compared them with parent AGS. The number of genes that were hypermethylated and decreased in expression and that were hypomethylated and increased in expression was 74.
Next, to evaluate whether alterations in the DNA methylation of these genes was related to expression change, gene expression change was measured by treatment with a demethylating agent. Twenty-one of those 74 genes increased in expression after treatment with decitabine (Table III) . Furthermore, gene expression and methylation were validated with quantitative methods, TaqMan PCR and bisulfite pyrosequencing, respectively, for FSCN1, CPT1C and NOTCH3.
Expression of these three genes increased after treatment with decitabine (Fig. 4) . FSCN1 revealed increased expression and hypomethylation in CDDPr compared with parent AGS cells. Regarding CPT1C, 5FUr showed hypomethylation and increased expression. CDDPr also showed increased expression, although the methylation level did not change. NOTCH3 showed increased expression and hypomethylation, especially in 5FUr. 
Discussion
The gene expression and the DNA methylation of drug-resistant cell lines and biopsy specimens were evaluated before and after chemotherapy, and some genes revealed altered expression and altered methylation. In drug-resistant cells, treatment with 5-FU and CDDP caused consistent expression change in >1,000 genes. In contrast, the expression of only a small number of genes changed reciprocally (Fig. 1) , and those genes were considered to be potentially related with drugspecific sensitivity. In GO analysis, only a small number of GO terms are commonly enriched in both 5-FU-resistant cells and CDDP-resistant cells, and enriched pathways related to the two drugs are also different. These findings may be related to differences in mechanisms of resistance to each drug.
Expression change of genes before and after chemotherapy was also evaluated using endoscopic biopsy specimens, and revealed that profiles of changes were different in the two patients. Expression of some genes increased or decreased, both in drug-resistant cells and biopsy specimens after chemotherapy (Fig. 2, Table II ). Such genes are considered to be candidates as key molecules for drug resistance, and may be useful as biomarkers of drug-sensitivity.
KLK13 is one member of the tissue kallikrein (KLK) family which includes 15 genes (KLK1-KLK15) and plays a role in tumor cell invasion and migration (13) . KLK13 has already been reported to be upregulated in gastric cancer cells after exposure to antineoplastic agents, including epirubicin and methotrexate (14) . It has also been reported that overexpression of KLK13 results in an increase of malignant cell behavior, and that knockdown of its endogenous gene expression causes a significant decrease in cell migratory and invasive properties (13) . We found that KLK13 increased in both drug-resistant cells and biopsy specimens, a finding suggesting that KLK13 may play a role in 5-FU and CDDP resistance in gastric cancer. In contrast to KLK13, expression of ETV7 decreased in drug-resistant cells. ETV7 is a member of the Ets transcription factor family and is reported to act as an inhibitor of differentiation (15) . Since ETV7 was downregulated in drug-resistant gastric cancer in the present study, it may be related with mechanisms of gastric cancer drug-sensitivity.
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In our experiment, CPT1C was increased in expression in 5-FU and CDDP-resistant cells, and demethylated in 5-FU-resistant cells. CPT1C has been reported to promote tumor growth and rapamycin resistance (18) . CPT1C expression correlates inversely with mammalian target of rapamycin (mTOR) pathway activation, contributes to rapamycin resistance in murine primary tumors, and is frequently upregulated in human lung tumors (18) . To our knowledge, there has been no report of a relationship between CPT1C and 5-FU or CDDP.
Notch is a transmembrane heterodimeric receptor with 4 distinct members (NOTCH1 to NOTCH4) present in humans. NOTCH3 is one of the Notch family members. It has been reported that NOTCH1, another molecule in Notch family members, expression is associated with cell aggressiveness and 5-FU drug resistance in human esophageal squamous cell carcinoma cell lines in vitro, and also with poor survival in human esophageal squamous cell carcinomas (19) . It has also been reported that expression levels of Notch3 were increased in rat tracheal epithelial cells after treatment with 5-FU (20) . NOTCH3 knockdown enhanced the sensitivity of nasopharyngeal carcinoma cells to CDDP treatment (21) , and NOTCH3 overexpression correlated with shorter progressionfree/overall survival in patients with advanced stage ovarian carcinoma treated with platinum and taxane (22) . In our data, NOTCH3 was upregulated in drug-resistant cells. In gastric cancer, NOTCH3 may be related to drug resistance.
However, we could not find a significant difference in methylation levels among biopsy samples. One of the limitations is that biopsy specimens may not represent the characteristics of the whole tumor, since gastric cancer is known to be biologically heterogeneous. 
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In the present study, genes with altered expression and DNA methylation were extracted after treatment with chemotherapeutic agents in gastric cancer. These alterations may be related to mechanisms of gastric cancer drug resistance, and may be useful as biomarkers that predict drug sensitivity. Further studies with a large number of clinical samples are necessary.
